ABOUT
ARCT‑810
The mRNA in ARCT-810 is designed to be a template for making OTC enzyme. Arcturus uses its lipid nanoparticle technology, called LUNAR®, to deliver the mRNA template for OTC to the liver, the place where OTC enzyme is made.
Animal studies show that:
ARCT-810 is taken into liver cells and releases the mRNA with the correct instructions to make functional OTC enzyme.
The mRNA is broken down over time and does not enter the nucleus, so it does not have the potential to alter or replace existing genes.
Therefore, it is believed that ARCT-810 will not cause permanent or irreversible changes to DNA.
If you have questions about the Arcturus clinical pipeline or platform, please contact us at clinicaltrials@arcturusrx.com
